Please turn JavaScript on
header-image

Cureresearch4type1diabetes

Want to stay in touch with the latest updates from Cureresearch4type1diabetes? That's easy! Just subscribe clicking the Follow button below, choose topics or keywords for filtering if you want to, and we send the news to your inbox, to your phone via push notifications or we put them on your personal page here on follow.it.

Reading your RSS feed has never been easier!

Website title: Current Research into Cures for Type-1 Diabetes

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.19 / week

Message History

CNK-UT009, as tested here, is a one-time infusion of living cells designed to modify the immune system’s behavior.  The idea behind it is that by reprogramming T cells, it may be possible to suppress the misdirected immune response that causes type 1 diabetes while potentially allowing remaining beta cells to function better.  Animal studies suggest that this meth...

Read full story

IMMUNOSTEM technology refers to using a virus (specifically a lentivirus) to deliver a new gene into cells, which will then produce a specific protein PD-L1 (Programmed Death-Ligand 1).  This protein plays a key role in the immune system by telling T-cells not to attack a specific other cell (in this case, beta cells).  This is done to the patient's own blood.&n...

Read full story

Baricitinib works by interfering with signaling pathways inside immune cells, to reduce inflammation and lower the immune system.  It is part of a class of drugs called Janus kinase (JAK) inhibitors.  JAK comes in two forms, JAK1 and JAK2, and Baricitinib targets both of them.

Baricitinib is not a new drug; it was first approved by th...

Read full story

This blog posting reports on the results of Avotres recent phase-I clinical trial into AVT001 and the company's future plans for testing.  I reported on the start of this trial here:

Read full story
Read full story